Cancer patients may soon have a new, exciting therapy option! The University of Texas MD Anderson Cancer Center and Federation Bio are teaming up to create a synthetic microbiome-based treatment. This new therapy will be made using a combination of Federation Bio’s cutting-edge ACTTM bacterial cell therapy platform and MD Anderson’s Platform for Innovative Microbiome and Translational Research (PRIME-TR). The goal of the collaboration is to help more cancer patients respond to immunotherapy treatments. Scientists have found that the gut microbiome plays a crucial role in determining if a patient will respond to checkpoint inhibitors, so the new therapy will be designed to enhance this response. Federation Bio has already used its platform to produce FB-001, a therapy that is being tested in a clinical trial. This exciting collaboration will bring a new hope for cancer patients and could dramatically improve their treatment outcomes.

https://www.mdanderson.org/newsroom/microbiome-therapy-collaboration-improve-immunotherapy-responses-announced-md-anderson-federation-bio.h00-159616278.html